Pharnext shares drop 40% as FDA requests second pivotal trial in CMT Sep. 3, 2019 By Cormac Sheridan No Comments DUBLIN – Shares in Pharnext SA plunged by more than 40% Friday on news that the FDA requires the company to undertake a second phase III trial of its Charcot-Marie-Tooth disease type 1A (CMT1A) therapy PXT-3003.Read More